Stay updated on Pembrolizumab in Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Medullary Thyroid Cancer Clinical Trial page
- Check3 days agoChange DetectedAdded Maryland as a study location under the Locations section (Bethesda, MD) and updated the revision to v3.3.3. The previous Maryland Locations entry and the HHS Vulnerability Disclosure link were removed (v3.3.2).SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedInternal site version update from v3.2.0 to v3.3.2 with no visible changes to study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check39 days agoChange DetectedA notice about government funding lapses and potential delays in updates and inquiries has been removed from the page. The NIH Clinical Center's operating status and data currency warnings are no longer displayed.SummaryDifference0.4%

- Check53 days agoChange DetectedUpdated results section now includes primary and secondary outcomes and there are revised contact and location details for participating sites.SummaryDifference0.4%

- Check82 days agoChange DetectedUpdated to v3.2.0 with an added government operating-status notice; removed the specific topic Medullary thyroid carcinoma (v3.1.0).SummaryDifference2%

- Check89 days agoChange DetectedUpdated the disease name to a streamlined term and bumped the revision to v3.1.0.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Medullary Thyroid Cancer Clinical Trial page.